Top Companies in the Biosurgery Market

The biosurgery market is projected to reach USD 21.59 billion by 2030 from USD 15.83 billion in 2025, at a CAGR of 6.4% from 2025 to 2030. The biosurgery market is predominantly driven by the rising frequency of elective surgical procedures and the increasing incidence of severe trauma cases. Additionally, the emphasis on effective hemorrhage management, the expanding geriatric population, and robust R&D efforts that are leading to a surge in new product launches are further propelling market expansion. The growing application of combination materials to enhance product performance, the rising adoption of adhesive dentistry techniques, and the substantial growth potential in emerging markets for minimally invasive surgeries present significant opportunities for stakeholders in this sector. Conversely, the market faces challenges such as a stringent regulatory landscape, a shortage of skilled personnel necessary to deploy biosurgery products effectively, and the high cost associated with these products, all of which could inhibit market growth during the forecast period.

Some of the major players in the biosurgery market with a significant global presence include Johnson & Johnson Services, Inc. (US), Baxter (US), Medtronic (Ireland), Becton, Dickinson and Company (BD) (US), B. Braun Melsungen AG (Germany), and Stryker (US). These players have incorporated various organic and inorganic growth strategies, including acquisitions, product launches, product approvals, and partnerships, to strengthen their international footprint and capture a greater share of the biosurgery market. These organic and inorganic strategies have allowed the market players to expand across geographies by offering biosurgery products.

1. In January 2025, Kuros Biosciences USA, Inc. entered into an exclusive strategic agreement with Medtronic’s Spinal Division, appointing Medtronic as the exclusive sales agent for MagnetOs in designated territories for spinal surgery applications.
2. In January 2024, Kuros Biosciences received US FDA 510(k) clearance for using MagnetOs Granules in interbody spinal procedures, along with regulatory approval for MagnetOs Granules and MagnetOs Putty in New Zealand.
3. In January 2023, Zimmer Biomet Holdings, Inc. announced that it has entered into a definitive agreement to acquire Embody, Inc., a company specializing in soft tissue healing, for USD 155 million at closing, with up to an additional USD 120 million contingent upon the achievement of future regulatory and commercial milestones over three years.
4. In October 2022, Orthofix Medical Inc. announced the full market release and first implants of Legacy Demineralized Bone Matrix (DBM), a putty for filling voids or gaps in boney defects or traumatic injuries of the spine, pelvis, or extremities.

To know about the assumptions considered for the study download the pdf brochure

Baxter (US) holds a prominent position in the global biosurgery market, driven by its diversified portfolio and robust innovation pipeline. Baxter's Advanced Surgery sub-segment within its Medical Products & Therapies division offers a comprehensive array of biosurgical solutions designed to improve surgical outcomes and address intraoperative hemorrhage across multiple specialties. These innovations are extensively utilized in critical care settings, including hospitals, ambulatory surgical centers, and rehabilitation facilities, highlighting Baxter's capability to cater to complex surgical demands. The company's leadership position in the biosurgery sector is bolstered by a robust global manufacturing and distribution network that spans over 100 countries, with operations in more than 20. Baxter strategically utilizes both direct and indirect sales channels to enhance its market presence. In 2024, the company is projected to invest USD 202 million in research and development within its Medical Products & Therapies segment, underscoring its commitment to ongoing innovation. This sustained investment facilitates continuous product development and refinement to meet evolving global surgical needs. With a strong regulatory record, an extensive global footprint, and a patient-centered approach, Baxter is well-equipped to tackle unmet needs in the biosurgery market, maintaining a competitive advantage in this critical field.

Johnson & Johnson Services, Inc. (US) commands a leading position in the global biosurgery market, driven by its expansive product portfolio, advanced R&D capabilities, and strong global footprint. Through its MedTech segment, specifically within the Surgery sub-segment, the company provides a comprehensive suite of biosurgery solutions that include hemostats, surgical sealants, adhesives, soft tissue attachments, adhesion barriers, hernia meshes, and staple line reinforcement agents. These products are integral to various surgical specialties, aimed at minimizing intraoperative complications and enhancing patient outcomes. The company maintains a leading position in the biosurgery market, bolstered by strong brand recognition among healthcare professionals, a robust manufacturing and distribution network, and ongoing investments in research and development. In FY 2024, the company dedicated USD 3,703 million to R&D within its MedTech segment, marking a 1.7% increase from the previous fiscal year—underscoring its commitment to continuous innovation and product lifecycle enhancement. With a global footprint and a strategic emphasis on innovation-driven growth, J&J adeptly addresses unmet clinical needs in complex surgical procedures. The company's ability to merge scientific expertise with customer-focused solutions solidifies its leadership in the biosurgery domain, enhancing its position as a reliable partner in surgical care on a global scale.

Market Ranking

The ranking of firms in the biosurgery market is based on market share analysis, secondary research, and validation from primary respondents. This rating considers revenue derived from product portfolio breadth and depth, innovation, and approvals/launches. The biosurgery market is competitive, with five main players collectively holding >50% of the total market share. The analysis states Johnson & Johnson Services, Inc. (US), Medtronic (Ireland), Baxter (US), Becton and Dickinson Company (BD) (US), and B Braun SE (Germany) as the top five players leading the biosurgery market. Baxter (US) stands out in the industry for its diverse portfolio of advanced biosurgery products, while Johnson & Johnson Services, Inc. (US) maintains a strong presence across the globe with its advanced portfolio of products for hernia mesh and fixation, adjunctive hemostasis, adhesion barrier, and staple line reinforcement. Additionally, Medtronic (Ireland) stands out for its significantly diverse portfolio across the globe. The company continuously involves itself in organic strategies to maintain its position in the market. Becton Dickinson and Company (BD) (US) and B Braun SE (Germany) stand out in offering advanced biosurgery products. The remaining <50% of the market is shared among other regional and emerging vendors, contributing to extensive fragmentation and offering opportunities for smaller players to establish a footprint.

Related Reports:

Biosurgery Market by Product (Bone Graft Substitutes, Sealants (Natural (Gelatin, Collagen)), Hemostatic Agents, Soft-tissue Attachments (Synthetic, Biological)), Application (Orthopedic, Urological), End User (Hospitals, ASCs) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com